WFRF:(Bogdanos Dimitrios)
Search: WFRF:(Bogdanos Dimitrios) > (2020) > Upadacitinib tartra...
- 3 of 4
- Previous record
- Next record
- To hitlist
Upadacitinib tartrate in rheumatoid arthritis
-
- Stamatis, Pavlos (author)
- Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,University of Thessaly,University Hospital of Larissa
-
- Bogdanos, Dimitrios P. (author)
- University Hospital of Larissa,University of Thessaly
-
- Sakkas, Lazaros (author)
- University of Thessaly,University Hospital of Larissa
- (creator_code:org_t)
- Clarivate Analytics (US), 2020
- 2020
- English.
- In: Drugs of Today. - : Clarivate Analytics (US). - 1699-3993. ; 56:11, s. 723-732
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- In rheumatoid arthritis (RA) there is an unmet therapeutic need, as a substantial proportion of patients does not achieve low disease activity or remission despite the use of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and/or biological DMARDs (bDMARDs). The Janus kinase (JAK) inhibitors are the most recently added drug category in the therapeutic armamentarium in RA. Upadacitinib tartrate (Rinvoq), a selective and reversible JAK1 inhibitor, inhibited interleukin (IL)-6 and IL-7 and ameliorated adjuvant-induced arthritis in preclinical studies. In phase III randomized controlled trials (RCTs), upadacitinib, as monotherapy or in combination with csDMARDs, showed efficacy in RA patients with inadequate response to csDMARDs or bDMARDs. In a head-to-head RCT, upadacitinib 15 mg once daily was superior to adalimumab in achieving remission and in patient-reported outcomes. Upadacitinib has a good safety profile but it may increase the risk for herpes zoster, and as a substrate of cytochrome P450 (CYP) enzyme CYP3A4 it should not be coadministered with strong CYP3A4 inducers. Upadacitinib is contraindicated in patients with active tuberculosis, serious infections, active malignancy and in patients with severe liver impairment. Upadacitinib has been approved for the treatment of moderate to severe RA.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Keyword
- Jak/STAT signaling
- RHEUMATOID ARTHRITIS
- JAK/STAT pathway
- Adverse Events
- pharmacokinetic
- pharmacodynamics
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
- Drugs of Today (Search for host publication in LIBRIS)
To the university's database
- 3 of 4
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Stamatis, Pavlos
- Bogdanos, Dimitr ...
- Sakkas, Lazaros
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Rheumatology and ...
- Articles in the publication
- Drugs of Today
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
